Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

BACKGROUND: HER2 (ERBB2) activating mutations are present in 2–3% of lung adenocarcinomas; however, no targeted therapy is approved for HER2-altered lung cancers. A novel pan-HER inhibitor, tarloxotinib, is designed to release the active form (tarloxotinib-E) under hypoxic conditions in tumor tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Takamasa, Suda, Kenichi, Nishino, Masaya, Fujino, Toshio, Ohara, Shuta, Hamada, Akira, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435395/
https://www.ncbi.nlm.nih.gov/pubmed/34584864
http://dx.doi.org/10.21037/tlcr-21-216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435395/
https://www.ncbi.nlm.nih.gov/pubmed/34584864
http://dx.doi.org/10.21037/tlcr-21-216

Ejemplares similares